scholarly journals Estimativa do Custo do Tratamento da Lesão por Pressão, Como Prevenir e Economizar Recursos

2018 ◽  
Vol 86 (24) ◽  
Author(s):  
Lívia Bertasso Araújo Portugal ◽  
Barbara Pompeu Christovam

O objetivo é estimar o custo hospitalar do tratamento da lesão por pressão e rever a literatura a respeito da prevençãode tais lesões. Estudo descritivo, retrospectivo, de março a dezembro de 2015, incluindo 58 pacientes, com um total de87 lesões por pressão, em uma unidade hospitalar de Niterói, Rio de Janeiro. Foram realizadas visitas aos setoresidentificando pacientes com lesão por pressão e as tecnologias utilizadas, e elaboração de planilha de custos e revisamosos métodos de prevenção à lesão por pressão. Foi encontrado um custo médio diário por paciente de R$ 14,24 e umcusto total de R$ 2992,03 para estes tratamentos. O tratamento da lesão por pressão teve um alto custo e exigiu aumentono tempo de internação. A revisão da literatura evidenciou modelos possíveis de serem adotados para atuar na prevençãodas lesões por pressão, os quais podem diminuir o tempo de internação e economizar recursos.Palavras-chave: Lesão por Pressão; Custos e Análise de Custo; Prevenção de Doenças. AbstractThe aim is to estimate the hospital costs of pressure-wound treatment and to review the literature regarding the injuriesprevention. Descriptive and retrospective study, from March to December 2015, including 58 patients, with a total of 87pressure injuries, in a hospital unit in Niterói, Rio de Janeiro. Visits were made to the sectors identifying patients withpressure injury and the used technologies, and elaboration of a cost sheet and we reviewed the pressure injureprevention methods. An average daily cost per patient of R$ 14.24 was found and a total cost of R$ 2992.03 for thesetreatments. The pressure lesion treatment had a high cost and demanded an increase in the hospitalization time. Theliterature review showed possible models to be adopted to act in the pressure injuries prevention, which can reducehospitalization time and save resources.Keywords: Pressure Ulcer; Costs and Cost Analysis; Disease Prevention.

2014 ◽  
Vol 1 (2) ◽  
pp. 156
Author(s):  
Erkan HAZAR ◽  
Ali Rıza İNCE ◽  
Selim ÇAM ◽  
Naim KARAGÖZ

Aim. The aim of this study is to investigate retrospectively the average cost per patient between the time 1May 2012-15 June 2013 in 68 patients who were hospitalized in the Burn Section of Numune State Hospital. Methods. This investigation includes age, degree of burn, burn percentage, burn type, hospitalization days and bills. Rates were determined according to the burn type of patients and costs were determined according to these types. Results. 80.9% of patients had hot water burn, 7.4% were burned due to burst flames, 4.4% had milk burns, 4.4% had steam burns and 2.9% were identified to have electrical burns. Average costs of burn injury inpatients was reported as TL values. Conclusion. The degree of burn injury, burn ratio and number of days during hospitalization were found to be dependent while age and type of burn injury were found to be independent variable that affect burn costs. The most important paramater that increased cost was number of days of hospitalization. Total cost of 68 patients was 1193,65 TL and average daily cost of a patient was found to be 110,12TL.


Author(s):  
CARINA ALMEIDA PIRES ◽  
THIAGO MOREIRA PESSOA ◽  
RUTH TRAMONTANI RAMOS ◽  
FÁBIO RAMOA PIRES ◽  
GERALDO OLIVEIRA SILVA ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15164-e15164
Author(s):  
Hugh J. Lavery ◽  
Adam W. Levinson ◽  
Adrien Phalen ◽  
Nelson Stone ◽  
Richard Stock ◽  
...  

e15164 Background: Radical prostatectomy (RP) and radiotherapy (RT) provide comparable HRQOL and oncologic outcomes of localized prostate cancer (PCa), yet no studies have evaluated their relative costs when investigated by risk group. We evaluated hospital costs associated with modern PCa therapies at a multidisciplinary program. Methods: Institutional billing data was queried for hospital patients from 2005 to 2009 with a primary admission for prostate cancer and primary procedure codes for RP, brachytherapy (BT), intensity modulated RT (IMRT) or combination treatment. All hospital costs related to the primary procedure were analyzed as assigned by the hospital. Costs were adjusted to 2009 USD and analyzed per patient and pretreatment D’Amico risk group. Results: 1969 localized PCa patients with a median age of 62 were identified with complete clinical information. There was a marked increase in the use of robotic-assisted laparoscopic prostatectomy (RALP) starting in 2007. The median total hospital costs for IMRT monotherapy ($16,673), BT+IMRT ($22,145) and RP+ adjuvant IMRT ($24,380) combination therapies were significantly higher than any other treatment type, although these patients had worse pathologic features. BT was the least expensive treatment with a total cost of $7,506, but was not routinely used as monotherapy for high-risk patients. The total cost of RALP ($7,676) was lower than open radical prostatectomy (RRP) ($8,991, p<0.001) and similar to laparoscopic radical prostatectomy (LRP) ($7,769).These trendsremained consistent when stratified by risk group (Table). Conclusions: In a high volume setting, RALP and BT are the least expensive modalities for treating low and intermediate risk PCa. For high risk patients, all forms of RP and IMRT alone were less expensive than combination therapy. [Table: see text]


2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Xin Zhang ◽  
Xiaoping Zhou ◽  
Xinyi Huang ◽  
Shumei Miao ◽  
Hongwei Shan ◽  
...  

Analysis of the related risks of disease provides a scientific basis for disease prevention and treatment, hospital management, and policy formulation by the changes in disease spectrum of patients in hospital. Retrospective analysis was made to the first diagnosis, age, gender, daily average cost of hospitalized patients, and other factors in the First Affiliated Hospital of Nanjing Medical University during 2006–2013. The top 4 cases were as follows: cardiovascular disease, malignant tumors, lung infections, and noninsulin dependent diabetes mellitus. By the age of disease analysis, we found a younger age trend of cardiovascular disease, and the age of onset of cancer or diabetes was somewhat postponed. The average daily cost of hospitalization and the average daily cost of the main noncommunicable diseases were both on the rise. Noncommunicable diseases occupy an increasingly important position in the constitution of the disease, and they caused an increasing medical burden. People should pay attention to health from the aspects of lifestyle changing. Hospitals should focus on building the appropriate discipline. On the other hand, an integrated government response is required to tackle key risks. Multiple interventions are needed to lower the burden of these diseases and to improve national health.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 2231-2231
Author(s):  
Omar Abughanimeh ◽  
Mohammad Tahboub ◽  
Anahat Kaur ◽  
Mouhanna Abu Ghanimeh ◽  
Zhang Zhiheng ◽  
...  

Abstract Background: Hereditarythrombophilias (HT) are a group of inherited diseases that predispose to venous thromboembolism (VTE). It can increase the risk of VTE by 3 to 20-fold compared to general population. HT are common and present in 7% of the population. Testing for HT is routine but knowing when to order the tests and how to interpret the results can be challenging. In the United Kingdom, it is estimated that 30,000 tests are done each year to screen for HT with an annual cost of 15,000,000 Euros. This led the British Committee For Standards in Haematology (BCSH) to release guidelines in 2010 that recommends against testing patients at the time of acute venous thrombosis as it will not influence the initial treatment. In the United States there are no clear guidelines regarding testing for HT. We performed a retrospective study to look at the utilization of HT tests among hospitalized patients. This study attempts to address the clinical utility of these tests and concurrent costs to the health care system. Methods: This is a retrospective study. We reviewed 2402 patient charts with at least one HT test ordered between 2/2016-1/2018 in St Luke's Health Care System records in Kansas City, MO. The following HT tests were included: Activated protein C resistance, antiphospholipid panel, antithrombin III level, factor V Leiden mutation, factor VIII level, homocysteine level, protein C level, protein S level, and prothrombin 20210 mutation. Only patients who had testing done during hospitalization were included. Positive actionable tests were analyzed to determine the clinical benefit of ordering the tests. A positive actionable test was defined as a positive test that changed the anticoagulation intensity, type or duration. Patients with history of previous thromboembolic disease, ongoing medical condition requiring life-long anticoagulation (such as atrial fibrillation), or unprovoked thromboembolic disease were considered non actionable. We also documented the total number of positive tests, ordering providers, and total cost related to ordering these tests (total cost of tests+ cost of hematology consult after an abnormal test). Results: A total of 2402 patients were reviewed. 954 patients were included with a mean age of 54 years. 397 (41.6%) were ordered for venous thromboembolism (VTE) (Deep vein thrombosis, pulmonary embolism or both). Among the included patients, 634 had at least one positive test (Table-1). Only 89 positive tests were actionable (14% of the positive tests and 9.3% of the total ordered tests). There was a statistically significant association between increasing age and having both a positive test result (P-value 0.006), and an actionable test (P-value 0.046). The chance of having actionable tests was more if the test was done in an inpatient setting rather that in the emergency room (OR 0.361, CI 95% (0.177-0.737)). The total cost of ordering these tests was estimated to be $551,218.1 and the cost of subsequent hematology consults was $15,367 leading to total cost of $566,585 during our study period. Conclusion: Inpatient testing for thrombophilia is associated with increased health care cost and did not change management in many situations. The decision of ordering these tests should be based on a clinical risk assessment. Disclosures No relevant conflicts of interest to declare.


Author(s):  
Haishaerjiang Wushouer ◽  
Zhenhuan Luo ◽  
Xiaodong Guan ◽  
Luwen Shi

Background: Chinese government established maximum retail prices for antibiotics listed in China’s National Reimbursement List in February 2013. This study aimed to analyze the impact of pharmaceutical price regulation on the price, volume and spending of antibiotics in China. Methods: An interrupted time series design with comparison series was used to examine impacts of the policy changes on average daily cost, monthly hospital purchase volume and spending of the 11 price-regulated antibiotics and 40 priceunregulated antibiotics in 699 hospitals. One intervention point was applied to assess the impact of policy. Results: After government price regulation, compared to price-unregulated antibiotics, the average daily cost of the price-regulated group declined rapidly (β=-5.68, P<.001). The average hospital monthly purchase spending of priceregulated antibiotics also decreased rapidly (β=-0.49, P<.010) and a positive trend change (β=0.04, P<.001) in average hospital spending of price-unregulated antibiotics was found. Conclusion: Government regulation can reduce the prices and spending of price-regulated antibiotics. To control increasing expenditure, besides price caps regulation, factors determining drug utilization also need to be considered in policy designing.


PEDIATRICS ◽  
1978 ◽  
Vol 61 (2) ◽  
pp. 170-170
Author(s):  
T. E. C.

In this era of skyrocketing hospital costs and dwindling purchasing power of the dollar, the total cost of a ten-day maternity stay in 1934 may be read with disbelief as will the long puerperal hospital stay. The time-honored custom of keeping women in bed nine days or more following delivery was generally observed until the mid-1940s. A hospital in Los Angeles charges $115 to $180 for a confinement case in a private room, $80 to $90 in a semiprivate room. The price includes all [italics mine] hospital services during a ten-days' stay: nursing, use of the delivery-room, anaesthetic, bandages, medicines, laboratory, and the feeding, nursing and clothing of the infant.


Author(s):  
Simone Costa Banna ◽  
Jaqueline Bulgarelli

Estudos na literatura revelam que o acesso ao diagnóstico e ao tratamento do câncer no Brasil é marcado pelas imensas desigualdades de oferta da assistência especializada, demora no diagnóstico e início do tratamento. Em relação à atenção terciária, a concentração dos recursos diagnósticos e terapêuticos, desejável para garantir maiores volumes e melhor qualidade do atendimento, muitas vezes impõem extensos deslocamentos a uma parcela considerável da população, sendo que, serviços especializados de cirurgia, radioterapia e quimioterapia estão concentrados nas cidades grandes, fazendo com que esta proporção considerável de pacientes que moram distantes desses serviços, estejam suscetíveis a uma menor sobrevida. O diagnóstico tardio revela a carência na quantidade e qualidade de serviços oncológicos fora das grandes capitais, assim como a baixa capacitação profissional na atenção oncológica, a incapacidade das unidades de saúde em absorver a demanda e as dificuldades dos gestores municipais e estaduais em definir e estabelecer um fluxo nos diversos níveis assistenciais. Em um país com as dimensões do Brasil, a distribuição desigual da população e dos serviços de saúde no território marca um desafio a ser enfrentado. Garantir o acesso da população aos diferentes níveis assistenciais é um dos sentidos atribuídos à integralidade através do artigo 196 da Constituição de 1988, que trata a saúde como direito de todos e dever do Estado, mediante políticas sociais e econômicas que visem à redução do risco de doença e de outros agravos. Conforme os termos do artigo 195, os custos de cuidados com a saúde devem ser realizados através de recursos do orçamento da seguridade social, da União, dos Estados, do Distrito Federal e dos Municípios, além de outras fontes. A vigente Política Nacional para a Prevenção e Controle do Câncer (Portaria 874/2013- GM/MS) busca contemplar em todas as unidades federadas ações de promoção, prevenção, diagnóstico, tratamento, reabilitação e cuidados paliativos, e apresenta a necessidade do cuidado integral ao usuário na Rede de Atenção à Saúde e estabelece que o tratamento do câncer seja realizado em estabelecimentos de saúde habilitados como Unidade de Assistência de Alta Complexidade em Oncologia (Unacon) ou como Centro de Assistência de Alta Complexidade em Oncologia (Cacon) de forma regionalizada e descentralizada, atuando de forma organizada e articulada com o Ministério da Saúde (MS) e com as Secretarias de Saúde dos estados e municípios. Desta forma, o Instituto Nacional do Câncer (INCA) que atua como órgão técnico e normativo do Ministério da Saúde (MS) no desenvolvimento e coordenação das ações integradas para a prevenção e controle do câncer no Brasil estimou no biênio 2019--2020, o surgimento de aproximadamente 600 mil novos casos de câncer no país, com exceção do câncer de pele não melanoma. Sendo que os tipos de câncer mais incidentes em homens serão próstata (31,7%), pulmão (8,7%), intestino (8,1%), estômago (6,3%) e cavidade oral (5,2%) e nas mulheres os com maior incidência serão os cânceres de mama (29,5%), intestino (9,4%), colo do útero (8,1%), pulmão (6,2%) e tireóide (4,0%). Em 2017, o custo total com tratamento de câncer no Brasil, foi de R$ 4,5 bilhões, sendo 48% deste valor destinado à quimioterapia, 10%, radioterapia e 7% na hormonioterapia. Os gastos com esses tratamentos totalizaram R$ 2,9 bilhões neste ano, enquanto procedimentos hospitalares chegaram a R$ 1,1 bilhão, representando 25% das despesas. No ano de 2018, R$ 4,6 bilhões, sendo que quimioterapia representou 49% das despesas, enquanto radioterapia e hormonioterapia ficaram responsáveis por 10% e 6% dos gastos, respectivamente. Os procedimentos hospitalares continuaram a representar 25% das despesas. Através de estatísticas do DATASUS nos anos de 2017 e 2018, foi estimado que cada paciente de câncer custou, em média, cerca de R$ 9 mil por ano para o sistema de saúde público brasileiro (R$ 9.107 em 2017 e R$ 9.157 em 2018). Com relação aos procedimentos realizados no SUS, observa-se um crescimento contínuo na quantidade de procedimentos de radioterapia, cirurgia e, principalmente, quimioterapia realizados nos últimos cinco anos. Isto indica que o uso dos serviços de saúde voltados para o tratamento de neoplasias vem aumentando no País com consequente aumento de custos associados. Investigar os custos de cuidados de saúde no SUS destinados para a atenção terciária em oncologia. Foi realizado uma revisão integrativa utilizando as bases de dados BVS, PubMed, Web of Science e Scopus, norteado com a pergunta de pesquisa: “O que os estudos na literatura destacam sobre os custos de cuidados de saúde no SUS destinados a atenção terciária em oncologia?”. A sintaxe utilizada para as bases de dados foi: ("Cost allocation" OR "Cost control" OR "Costs and cost analysis" OR "Health care costs" OR "Hospital costs") AND ("Oncology" OR "Cancer institutes" OR "Hospital service of Oncology") AND ("Outpatient care" OR "Tertiary health care" OR "Third level of health care" OR "Unified health system"). O total de estudos identificados nas bases de dados BVS, PubMed, Web of Science e Scopus, foram 59 estudos, 8 estudos no Google acadêmico, totalizando 67 estudos. Foram excluídos 3 duplicatas e 1 assunto diferente do artigo em estudo e 31 estudos excluídos após a leitura de títulos e resumos. Realizada a leitura na íntegra de 32 estudos e selecionados 9 estudos para inclusão na revisão. A garantia da integralidade da saúde e da aplicabilidade correta dos recursos destinados para a atenção terciária no SUS necessita de uma gestão eficiente assim como de estratégias advindas da economia da saúde para que pacientes oncológicos em tratamento possam ter acesso digno, eficiente e de qualidade, adequado às condições de vida destas pessoas, considerando sua região, condição econômica e estágio da doença.


2016 ◽  
Vol 14 (1) ◽  
pp. 41-46 ◽  
Author(s):  
Valesca Nunes dos Reis ◽  
Isabella Bertolin Paixão ◽  
Ana Carolina Amaral de São José Perrone ◽  
Maria Inês Monteiro ◽  
Kelli Borges dos Santos

ABSTRACT Objective To analyze the process of recording transfusion monitoring at a public teaching hospital. Methods A descriptive and retrospective study with a quantitative approach, analyzing the instruments to record transfusion monitoring at a public hospital in a city in the State of Minas Gerais (MG). Data were collected on the correct completion of the instrument, time elapsed from transfusions, records of vital signs, type of blood component more frequently transfused, and hospital unit where transfusion was performed. Results A total of 1,012 records were analyzed, and 53.4% of them had errors in filling in the instruments, 6% of transfusions started after the recommended time, and 9.3% of patients had no vital signs registered. Conclusion Failures were identified in the process of recording transfusion monitoring, and they could result in more adverse events related to the administration of blood components. Planning and implementing strategies to enhance recording and to improve care delivered are challenging.


2017 ◽  
Vol 15 (2) ◽  
pp. 192-199
Author(s):  
Adriano Hyeda ◽  
Élide Sbardellotto Mariano da Costa

ABSTRACT Objective To conduct an economic analysis of enteral and parenteral diet costs according to the type of disease and outcome (survivors versus deaths). Methods It is a cross-sectional, observational, retrospective study with a qualitative and quantitative design, based on analysis of hospital accounts from a healthcare insurance provider in the Southern region of Brazil. Results We analyzed 301 hospital accounts of individuals who used enteral and parenteral diets. The total cost of the diet was 35.4% of hospital account total costs. The enteral modality accounted for 59.8% of total dietary costs. The major costs with diets were observed in hospitalizations related to infections, cancers and cerebro-cardiovascular diseases. The major costs with parenteral diet were with admissions related by cancers (64.52%) and dementia syndromes (46.17%). The highest ratio between total diet costs with the total of hospital account costs was in dementia syndromes (46.32%) and in cancers (41.2%). The individuals who died spent 51.26% of total of hospital account costs, being 32.81% in diet (47.45% of total diet value and 58.81% in parenteral modality). Conclusion Enteral and parenteral nutritional therapies account for a significant part of the costs with hospitalized individuals, especially in cases of cancers and dementia syndromes. The costs of parenteral diets were higher in the group of patients who died.


Sign in / Sign up

Export Citation Format

Share Document